Related Experiment Videos
Severe Coxsackie virus B infection in preterm newborns treated with pleconaril
Sofia Bauer1, Giora Gottesman, Lea Sirota
1Neonatal Intensive Care Unit, Meir General Hospital, Kfar-Saba, The Sackler School of Medicine, Tel Aviv University, Israel.
Insights
Oral pleconaril effectively treated severe Coxsackie virus B infection in four preterm infants. All infants recovered with no adverse effects, suggesting potential for this antiviral therapy.
Area of Science:
- Neonatal infectious diseases
- Virology
- Pediatric critical care
Background:
- Severe Coxsackie virus B infection poses a significant threat to preterm neonates.
- Multisystem involvement, including myocarditis, hepatitis, and meningoencephalitis, indicates a grave prognosis.
Observation:
- Four preterm infants presented with severe, multisystem Coxsackie virus B infection.
- Clinical manifestations included myocarditis, fulminant hepatitis, meningoencephalitis, and disseminated intravascular coagulopathy.
Findings:
- Treatment with oral pleconaril (5 mg/kg/day) led to complete recovery in all four infants.
- No adverse effects were observed during or after pleconaril administration.
Implications:
- Pleconaril demonstrates promising efficacy and safety for treating severe enteroviral infections in neonates.
- Further comprehensive clinical evaluation of pleconaril in this vulnerable population is warranted.
Unlabelled:
Four preterm newborn infants with severe multisystem Coxsackie virus B infection were treated with an oral suspension of pleconaril (5 mg/kg per day). The patients had myocarditis, fulminant hepatitis, meningoencephalitis and disseminated intravascular coagulopathy. All four infants recovered, and no adverse effects of the treatment were noted.
Conclusion:
pleconaril needs to be comprehensively evaluated in this population.